Chronic Lymphocytic Leukemia Market 2018 : Eli Lilly and Co, F. Hoffmann-La Roche Ltd, GeneaMed Ltd, Iovance Biotherapeutics Inc, Johnson & Johnson, Xencor Inc, and ZIOPHARM Oncology Inc.

Chronic lymphocytic leukemia (CLL)

Overview

Chronic lymphocytic leukaemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2574817-chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2017

Chronic Lymphocytic Leukemia (CLL) Industry Major Highlights:

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology),  complete analysis of drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The report further guide in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. . Apart from this various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Major Outlook for Chronic Lymphocytic Leukemia (CLL) Report:

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL)

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL).

- The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources.

Competitive Analysis for Chronic Lymphocytic Leukemia (CLL)

Key players are making innovative developments in Chronic Lymphocytic Leukemia (CLL) industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector.

The key players in this market are 4SC AG, AbbVie Inc, Baliopharm AG, Celltrion Inc, Debiopharm International SA, Eli Lilly and Co, F. Hoffmann-La Roche Ltd, GeneaMed Ltd, Iovance Biotherapeutics Inc, Johnson & Johnson, Xencor Inc, and ZIOPHARM Oncology Inc.

….. Continued

Table of Contents

Introduction 5

Global Markets Direct Report Coverage 5

Chronic Lymphocytic Leukemia (CLL) - Overview 6

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 10

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 11

Assessment by Target 11

Assessment by Mechanism of Action 13

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 19

ActiveSite Pharmaceuticals Inc 19

Coherus BioSciences Inc 19

Lupin Ltd 20

Mabion SA 20

....

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2574817-chronic-lymphocytic-leukemia-cll-pipeline-review-h2-2017

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)